{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T12:26:14Z","timestamp":1787401574192,"version":"build-2736575974"},"reference-count":26,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["2UG1DA049444"],"award-info":[{"award-number":["2UG1DA049444"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Use &amp; Addiction Journal"],"abstract":"<jats:p>Opioid use disorder (OUD) treatment needs continue to outpace the capacity of existing treatment systems, with access to buprenorphine particularly constrained in many communities. Pharmacist involvement in medications for OUD (MOUD), including buprenorphine initiation and longitudinal management, has demonstrated feasibility and acceptability in select settings, yet widespread implementation remains limited by regulatory variability and fragmented care models. Pharmacies are highly accessible health care sites, and pharmacists\u2019 scope of practice can be expanded through mechanisms such as collaborative pharmacy practice agreements (CPPAs)\u2014a term used interchangeably in the literature with \u201ccollaborative practice agreement\u201d and related variants\u2014to support buprenorphine initiation and ongoing management. The CTN-0151 PharmValue project aims to develop a scalable, pharmacist-led CPPA model for MOUD that can be adapted across diverse state regulatory environments and pharmacy settings. Using a community-engaged research approach and a 50-state legal and regulatory review supplemented by a national expert survey, PharmValue will (1) engage community stakeholders to codevelop a model CPPA and care pathway for pharmacist-managed buprenorphine and (2) identify existing legal authorities and advocacy opportunities to expand pharmacist-managed MOUD care nationally. This protocol commentary describes the rationale, guiding frameworks, and key design decisions underlying the PharmValue model and outlines anticipated implementation challenges and future directions for evaluation and scale-up.<\/jats:p>","DOI":"10.1177\/29767342261475107","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T01:32:22Z","timestamp":1787103142000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Toward a Pharmacy-Led Value-Based Care Model for Buprenorphine Initiation and Management (PharmValue): Development of a Scalable Pharmacist-Led Collaborative Practice Agreement for Medications for Opioid Use Disorder"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0060-4643","authenticated-orcid":false,"given":"Kenneth C.","family":"Hohmeier","sequence":"first","affiliation":[{"name":"University of Tennessee Health Science Center, Department of Clinical Pharmacy and Translational Science, Memphis, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Barenie","sequence":"additional","affiliation":[{"name":"University of Tennessee Health Science Center, Department of Clinical Pharmacy and Translational Science, Memphis, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Tyszko","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, University of Utah, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Cox","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, University of Utah, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8908-9686","authenticated-orcid":false,"given":"John A.","family":"Saunders","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, University of Utah, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2297-9702","authenticated-orcid":false,"given":"Kristi","family":"Carlston","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, University of Utah, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, University of Utah, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0153-0252","authenticated-orcid":false,"given":"Gerald","family":"Cochran","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, University of Utah, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2015.302664"},{"issue":"2","key":"e_1_3_2_3_2","article-title":"Opioid use disorder: treatments and barriers","volume":"13","author":"Patel K","year":"2021","unstructured":"Patel K, Bunachita S, Agarwal AA, Lyon A, Patel UK. Opioid use disorder: treatments and barriers. Cureus. 2021; 13(2):e13173.","journal-title":"Cureus"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/PRA.0000000000000437"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/M18-3457"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2020.1787300"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxy089"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2024.102319"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.15353"},{"key":"e_1_3_2_10_2","first-page":"10","article-title":"Developing community pharmacist prescribing models to expand access to medications for opioid use disorder","author":"Bacci JL","year":"2024","unstructured":"Bacci JL, Zhang B, Brackeen S, Arnold J, English CD, Hansen RN. Developing community pharmacist prescribing models to expand access to medications for opioid use disorder. J Addict Med. 2024:10-97.","journal-title":"J Addict Med"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2021.10.002"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.27418"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2025.102425"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/08897077231203849"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-019-0158-0"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/jac5.1137"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2022.07.003"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-024-00452-y"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2208055"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001154"},{"key":"e_1_3_2_21_2","volume-title":"Practical Tools for Prescribing and Promoting Buprenorphine in Primary Care Settings. SAMHSA Publication No PEP21-06-01-002","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)","year":"2021","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). Practical Tools for Prescribing and Promoting Buprenorphine in Primary Care Settings. SAMHSA Publication No PEP21-06-01-002. National Mental Health and Substance Use Policy Laboratory, Substance Abuse and Mental Health Services Administration; 2021."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000633"},{"key":"e_1_3_2_23_2","volume-title":"Advancing Team-Based Care Through Collaborative Practice Agreements: A Resource and Implementation Guide for Adding Pharmacists to the Care Team","author":"Centers for Disease Control and Prevention","year":"2017","unstructured":"Centers for Disease Control and Prevention. Advancing Team-Based Care Through Collaborative Practice Agreements: A Resource and Implementation Guide for Adding Pharmacists to the Care Team. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services; 2017."},{"key":"e_1_3_2_24_2","volume-title":"Pharmacists and Buprenorphine: Analysis of State Laws and Regulations","author":"Legislative Analysis and Public Policy Association","year":"2025","unstructured":"Legislative Analysis and Public Policy Association. Pharmacists and Buprenorphine: Analysis of State Laws and Regulations. Legislative Analysis and Public Policy Association; 2025. Research current as of October 2024."},{"key":"e_1_3_2_25_2","unstructured":"Pharmacy Bridge [website]. 2026. https:\/\/www.pharmacybridge.org. Accessed May 19 2026."},{"key":"e_1_3_2_26_2","volume-title":"Model Expanded Access to Emergency Opioid Antagonists Act","author":"Legislative Analysis and Public Policy Association","year":"2021","unstructured":"Legislative Analysis and Public Policy Association. Model Expanded Access to Emergency Opioid Antagonists Act. LAPPA; 2021."},{"key":"e_1_3_2_27_2","volume-title":"The Pharmacy Access to Resources and Medication for Opioid Use Disorder (PhARM-OUD) Guideline","author":"National Association of Boards of Pharmacy, National Community Pharmacists Association","year":"2024","unstructured":"National Association of Boards of Pharmacy, National Community Pharmacists Association. The Pharmacy Access to Resources and Medication for Opioid Use Disorder (PhARM-OUD) Guideline. National Association of Boards of Pharmacy, National Community Pharmacists Association; 2024."}],"container-title":["Substance Use &amp; Addiction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342261475107","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/29767342261475107","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342261475107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T11:50:56Z","timestamp":1787399456000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/29767342261475107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":26,"alternative-id":["10.1177\/29767342261475107"],"URL":"https:\/\/doi.org\/10.1177\/29767342261475107","relation":{},"ISSN":["2976-7342","2976-7350"],"issn-type":[{"value":"2976-7342","type":"print"},{"value":"2976-7350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"article-number":"29767342261475107"}}